Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warns Again Of Rare Cancer Associated With TNF Blockers

Executive Summary

FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.

You may also be interested in...

FDA Boosts Surveillance Requirements For TNF Blockers In Effort To Track Lymphoma

Manufacturers must conduct in-depth follow-up of reported malignancies in children and young adult patients and submit them to FDA within 15 days of learning about the cases.

FDA Skeptical Of Maintenance Claims For Centacor's Remicade In Pediatric Ulcerative Colitis

Agency accepts 8-week efficacy, but says long-term data is sparse for the tumor necrosis factor inhibitor, which goes before the Gastrointestinal Drugs Advisory Committee July 21.

Remicade Pediatric Indication Likely Faces Safety Scrutiny At Advisory Committee

Risks of cancer and fungal infections are likely to grab a great deal of attention from the Gastrointestinal Drugs Advisory Committee when it reviews Centocor Ortho Biotech's Remicade (infliximab) for children July 21.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts